\-\ Texto\\:\\ \ \(0\)\
\-\ \\'enlarged\\ liver\\'\\ \\-\\ otherwise\\ unremarkable\ \(0\)\
\-\ no\\ clinical\\ evidence\\ of\\ hypertension\ \(0\)\
\-\ cbc\\ \\-\\ within\\ normal\\ limits\ \(0\)\
\-\ serum\\ and\\ urine\\ metanephrines\\ \\-\\ within\\ normal\\ limits\ \(0\)\
\-\ 24\\-hour\\ urine\\ \\-\\ within\\ normal\\ limits\ \(0\)\
\-\ further\\ evaluation\\ is\\ underway\\ to\\ determine\\ exact\\ subtype\\ of\\ b\\-cell\\ lymphoma\\ prior\\ to\\ initiation\\ of\\ treatment\\.\ \(0\)\
\-\ 10\\ cm\\ abdominal\\ enhancing\\ mass\\ superior\\ to\\ right\\ kidney\\,\\ with\\ internal\\ flow\\ on\\ ultrasound\\,\\ distinct\\ from\\ adrenal\\ gland\\.\\ \\ no\\ abdominal\\ or\\ pelvic\\ lymphadenopathy\\.\ \(0\)\
\-\ non\\-hodgkin\\'s\\ lymphoma\\ \\-\\ b\\-cell\\ lymphoma\ \(0\)\
\-\ pancreatic\\ carcinoma\ \(8\)\
\-\ pheochromocytoma\ \(23\)\
\-\ lymphoma\ \(373\)\
\-\ 60\\ year\\-old\\ man\\ with\\ enlarged\\ liver\\ by\\ physical\\ exam\\.\ \(1\)\
\-\ initial\\ biopsy\\ revealed\\ that\\ the\\ tumor\\ cells\\ are\\ strongly\\ positive\\ for\\ cd20\\ and\\ focally\\ positive\\ for\\ cd99\\;\\ but\\ negative\\ for\\ cytokeratin\\,\\ s100\\,\\ and\\ mesenchymal\\ markers\\ consistent\\ with\\ atypical\\ b\\-cell\\ lymphoma\\.\ \(0\)\
\-\ follow\\-up\\ flow\\ cytometry\\ revealed\\ that\\ predominant\\ cell\\ population\\ are\\ b\\-cells\\ expressing\\ cd45\\,\\ cd20\\ \\(bright\\)\\,\\ cd19\\,\\ cd10\\,\\ fmc\\-7\\ and\\ cd38\\.\\ \\ the\\ kappa\\ to\\ lambda\\ ratio\\ is\\ greater\\ than\\ 1\\:100\\,\\ lambda\\ light\\ chain\\ restricted\\.\\ \\ they\\ are\\ negative\\ for\\ cd34\\,\\ cd5\\,\\ and\\ cd23\\.\\ differential\\ diagnosis\\ includes\\ diffuse\\ large\\ b\\-cell\\ lymphoma\\ and\\ burkitt\\'s\\ lymphoma\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ b\\-cell\\:\\ 0\\.11081272630208369\ \(0\)\
\-\ lymphoma\\:\\ 0\\.08903849187878334\ \(0\)\
\-\ lambda\\:\\ 0\\.07316415577852545\ \(0\)\
\-\ cd20\\:\\ 0\\.07155841953032484\ \(0\)\
\-\ limits\\:\\ 0\\.055034587488156345\ \(0\)\
\-\ \\-\\:\\ 0\\.0477012619455303\ \(0\)\
\-\ \\'enlarged\\:\\ 0\\.04591415845815884\ \(0\)\
\-\ underway\\:\\ 0\\.04591415845815884\ \(0\)\
\-\ expressing\\:\\ 0\\.04591415845815884\ \(0\)\
\-\ fmc\\-7\\:\\ 0\\.04591415845815884\ \(0\)\
\-\ cd38\\:\\ 0\\.04591415845815884\ \(0\)\
\-\ cd34\\:\\ 0\\.04591415845815884\ \(0\)\
\-\ urine\\:\\ 0\\.04296010980976411\ \(0\)\
\-\ cd99\\:\\ 0\\.04230401689274246\ \(0\)\
\-\ s100\\:\\ 0\\.04230401689274246\ \(0\)\
\-\ b\\-cells\\:\\ 0\\.04230401689274246\ \(0\)\
\-\ cd45\\:\\ 0\\.04230401689274246\ \(0\)\
\-\ cd19\\:\\ 0\\.04230401689274246\ \(0\)\
\-\ 1\\:100\\:\\ 0\\.04230401689274246\ \(0\)\
\-\ cd23\\:\\ 0\\.04230401689274246\ \(0\)\
\-\ metanephrines\\:\\ 0\\.03869387532732608\ \(0\)\
\-\ kappa\\:\\ 0\\.03869387532732608\ \(0\)\
\-\ cd5\\:\\ 0\\.03869387532732608\ \(0\)\
\-\ cd10\\:\\ 0\\.0375316693308979\ \(0\)\
\-\ cytokeratin\\:\\ 0\\.03577920976516242\ \(0\)\
\-\ cytometry\\:\\ 0\\.03577920976516242\ \(0\)\
\-\ initiation\\:\\ 0\\.03447028045119936\ \(0\)\
\-\ burkitt\\:\\ 0\\.03392152776548152\ \(0\)\
\-\ 24\\-hour\\:\\ 0\\.03297193632384634\ \(0\)\
\-\ liver\\:\\ 0\\.030689807404507538\ \(0\)\
\-\ subtype\\:\\ 0\\.03005727076168268\ \(0\)\
\-\ mesenchymal\\:\\ 0\\.03005727076168268\ \(0\)\
\-\ chain\\:\\ 0\\.03005727076168268\ \(0\)\
\-\ focally\\:\\ 0\\.02981497901358428\ \(0\)\
\-\ non\\-hodgkin\\:\\ 0\\.02958345941686119\ \(0\)\
\-\ markers\\:\\ 0\\.02958345941686119\ \(0\)\
\-\ flow\\:\\ 0\\.029417227883942874\ \(0\)\
\-\ positive\\:\\ 0\\.02888422489879288\ \(0\)\
\-\ pheochromocytoma\\:\\ 0\\.02874834144771963\ \(0\)\
\-\ predominant\\:\\ 0\\.02874834144771963\ \(0\)\
\-\ revealed\\:\\ 0\\.028567436352771803\ \(0\)\
\-\ exact\\:\\ 0\\.02754769739244967\ \(0\)\
\-\ negative\\:\\ 0\\.026584585014321607\ \(0\)\
\-\ distinct\\:\\ 0\\.026447129196266298\ \(0\)\
\-\ within\\:\\ 0\\.025470803256032525\ \(0\)\
\-\ strongly\\:\\ 0\\.02476601777822958\ \(0\)\
\-\ ratio\\:\\ 0\\.024676984271149886\ \(0\)\
\-\ population\\:\\ 0\\.023222966652483888\ \(0\)\
\-\ \\'\\:\\ 0\\.022594695882751516\ \(0\)\
\-\ determine\\:\\ 0\\.022535844032470616\ \(0\)\
\-\ adrenal\\:\\ 0\\.022535844032470616\ \(0\)\
\-\ bright\\:\\ 0\\.022251164800502574\ \(0\)\
\-\ abdominal\\:\\ 0\\.0222491587304387\ \(0\)\
\-\ pancreatic\\:\\ 0\\.021774944977796157\ \(0\)\
\-\ serum\\:\\ 0\\.021480054904882057\ \(0\)\
\-\ normal\\:\\ 0\\.020931444603110954\ \(0\)\
\-\ light\\:\\ 0\\.020766691076376027\ \(0\)\
\-\ restricted\\:\\ 0\\.02048289844468816\ \(0\)\
\-\ cbc\\:\\ 0\\.019887011198970746\ \(0\)\
\-\ \\'s\\:\\ 0\\.019625485607990052\ \(0\)\
\-\ 60\\:\\ 0\\.01941626087882351\ \(0\)\
\-\ atypical\\:\\ 0\\.019289222060468514\ \(0\)\
\-\ gland\\:\\ 0\\.01895504526767015\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.018925702467054235\ \(0\)\
\-\ pelvic\\:\\ 0\\.018266930867527568\ \(0\)\
\-\ are\\:\\ 0\\.018201154258275027\ \(0\)\
\-\ includes\\:\\ 0\\.017942085394993933\ \(0\)\
\-\ cells\\:\\ 0\\.017846076532031234\ \(0\)\
\-\ hypertension\\:\\ 0\\.01754573464739681\ \(0\)\
\-\ greater\\:\\ 0\\.016717272696200526\ \(0\)\
\-\ year\\-old\\:\\ 0\\.01634773240467821\ \(0\)\
\-\ they\\:\\ 0\\.016036177742121384\ \(0\)\
\-\ otherwise\\:\\ 0\\.015986016840762212\ \(0\)\
\-\ biopsy\\:\\ 0\\.015790068966858126\ \(0\)\
\-\ kidney\\:\\ 0\\.015679080495052133\ \(0\)\
\-\ \\,\\:\\ 0\\.015509430836927922\ \(0\)\
\-\ that\\:\\ 0\\.015374799255821076\ \(0\)\
\-\ for\\:\\ 0\\.01518975309672323\ \(0\)\
\-\ enlarged\\:\\ 0\\.015185526408250032\ \(0\)\
\-\ 10\\:\\ 0\\.015003251189306824\ \(0\)\
\-\ internal\\:\\ 0\\.014921228496764433\ \(0\)\
\-\ initial\\:\\ 0\\.014747823662913061\ \(0\)\
\-\ unremarkable\\:\\ 0\\.014734720930635731\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.01447935933042574\ \(0\)\
\-\ superior\\:\\ 0\\.01421220675549058\ \(0\)\
\-\ further\\:\\ 0\\.014153354905209678\ \(0\)\
\-\ differential\\:\\ 0\\.014129999111213175\ \(0\)\
\-\ enhancing\\:\\ 0\\.01395809131710812\ \(0\)\
\-\ clinical\\:\\ 0\\.013694321875343772\ \(0\)\
\-\ diffuse\\:\\ 0\\.01347399698112143\ \(0\)\
\-\ ultrasound\\:\\ 0\\.013203763463574495\ \(0\)\
\-\ evaluation\\:\\ 0\\.012928327061597956\ \(0\)\
\-\ carcinoma\\:\\ 0\\.01261420661466597\ \(0\)\
\-\ cell\\:\\ 0\\.012022087039486908\ \(0\)\
\-\ cm\\:\\ 0\\.011937271446963467\ \(0\)\
\-\ evidence\\:\\ 0\\.011668971788369155\ \(0\)\
\-\ than\\:\\ 0\\.011661712786032676\ \(0\)\
\-\ prior\\:\\ 0\\.011427670688553975\ \(0\)\
\-\ physical\\:\\ 0\\.01091929827906895\ \(0\)\
\-\ consistent\\:\\ 0\\.010913011816829183\ \(0\)\
\-\ \\;\\:\\ 0\\.010549068689857258\ \(0\)\
\-\ man\\:\\ 0\\.010525686682760412\ \(0\)\
\-\ tumor\\:\\ 0\\.010376209904222975\ \(0\)\
\-\ diagnosis\\:\\ 0\\.010219892347814686\ \(0\)\
\-\ exam\\:\\ 0\\.009777260103903843\ \(0\)\
\-\ large\\:\\ 0\\.009731991832453539\ \(0\)\
\-\ but\\:\\ 0\\.009492204692883009\ \(0\)\
\-\ treatment\\:\\ 0\\.009008421664587953\ \(0\)\
\-\ no\\:\\ 0\\.008962959903164603\ \(0\)\
\-\ to\\:\\ 0\\.00889725225922888\ \(0\)\
\-\ by\\:\\ 0\\.007410785954400389\ \(0\)\
\-\ from\\:\\ 0\\.006596019339344856\ \(0\)\
\-\ mass\\:\\ 0\\.006189901077851898\ \(0\)\
\-\ is\\:\\ 0\\.005857195608174225\ \(0\)\
\-\ and\\:\\ 0\\.005625281429131827\ \(0\)\
\-\ or\\:\\ 0\\.005216264317519309\ \(0\)\
\-\ right\\:\\ 0\\.004695998484950087\ \(0\)\
\-\ on\\:\\ 0\\.003770265689403271\ \(0\)\
\-\ \\(\\:\\ 0\\.0037623006575201066\ \(0\)\
\-\ \\)\\:\\ 0\\.0037163421464234637\ \(0\)\
\-\ with\\:\\ 0\\.0018281902514045271\ \(0\)\
\-\ of\\:\\ 0\\.0018203718874685692\ \(0\)\
\-\ \\.\\:\\ 0\\.0016640407545631068\ \(0\)\
\-\ the\\:\\ 0\\.0014400967156627687\ \(0\)\
